Excess Ticagrelor Mortality in the Food and Drug Administration Adverse Event Reporting System: Time to Recount PLATO Trial Deaths.
Department of Neurology, Johns Hopkins University, Baltimore, Md; HeartDrug Research Laboratories, Towson, Md.
Victor L
VL
Serebruany
HeartDrug Research Laboratories, Towson, Md.
Seth D
SD
Fortmann
HeartDrug Research Laboratories, Towson, Md.
Vasily
V
Cherepanov
HeartDrug Research Laboratories, Towson, Md.
Oleg
O
Litvinov
Department of Cardiology, Dong-A University, Busan, South Korea.
Moo Hyun
MH
Kim
Retired from the US Food and Drug Administration, Bethesda, Md.
Thomas A
TA
Marciniak
D000241:Adenosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016907:Adverse Drug Reaction Reporting Systems; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000401:mortality*; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000401:mortality*; D006801:Humans; D058921:Purinergic P2Y Receptor Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000077486:Ticagrelor; D014481:United States / Q000453:epidemiology; D014486:United States Food and Drug Administration
D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine